Second, TNBC has higher levels of PD-L1 expression in tumor and immune cells (according to The Cancer Genome Atlas, it has been confirmed that TNBC has a higher expression of PD-L1 mRNA) [84,85], providing a direct response to anti-PD-1 therapy. Here, CD274 is linked to neoplasm.